AstraZeneca PLC Total Assets
AstraZeneca PLC total assets. Based on the latest financial reports, AstraZeneca PLC (AZN) holds total assets worth $114.02 Billion USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see AZN company net worth for the company's overall valuation and market capitalisation.
Total Assets of AstraZeneca PLC (1990–2025)
Total assets of AstraZeneca PLC from 1990 to 2025. This chart illustrates how AstraZeneca PLC's total assets have evolved over time, based on quarterly financial data. See AZN live share price for real-time trading data and today's change.
AstraZeneca PLC - Asset Composition Analysis
AstraZeneca PLC Total Assets Breakdown (December 2025)
AstraZeneca PLC total assets breakdown as of December 2025. AstraZeneca PLC's total assets of $114.02 Billion consist of 25.2% current assets and 74.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $4.38 Billion | 5.0% |
| Accounts Receivable | $15.18 Billion | 13.3% |
| Inventory | $6.56 Billion | 5.8% |
| Property, Plant & Equipment | $14.70 Billion | 12.9% |
| Intangible Assets | $37.85 Billion | 33.2% |
| Goodwill | $21.24 Billion | 18.6% |
Asset Composition Trend (1990–2025)
This chart illustrates how AstraZeneca PLC's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore AZN current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AstraZeneca PLC's current assets represent 25.2% of total assets in 2025, a decrease from 58.1% in 1990.
- Cash Position: Cash and equivalents constituted 5.0% of total assets in 2025, up from 2.1% in 1990.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 51.0% of total assets, an increase from 0.0% in 1990.
- Asset Diversification: The largest asset category is intangible assets at 33.2% of total assets.
AstraZeneca PLC Competitors by Total Assets
Key competitors of AstraZeneca PLC based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
SHE:301096
|
China | CN¥3.80 Billion |
|
GuangYuYuan Chinese Herbal Medicine Co Ltd
SHG:600771
|
China | CN¥2.55 Billion |
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF100.70 Billion |
|
Sanofi
F:SNW2
|
Germany | €129.79 Billion |
|
Sichuan Kelun Pharmaceutical Co Ltd
SHE:002422
|
China | CN¥41.49 Billion |
|
Grifols S.A
F:G0FB
|
Germany | €19.71 Billion |
|
TTK Healthcare Limited
NSE:TTKHLTCARE
|
India | Rs13.29 Billion |
|
Eli Lilly and Company
NYSE:LLY
|
USA | $142.28 Billion |
AstraZeneca PLC - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.91 | 0.90 | 1.23 |
| Quick Ratio | 0.71 | 0.70 | 1.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-2.96 Billion | $-2.99 Billion | $5.05 Billion |
AstraZeneca PLC - Advanced Valuation Insights
This section examines the relationship between AstraZeneca PLC's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.99 |
| Latest Market Cap to Assets Ratio | 2.47 |
| Asset Growth Rate (YoY) | 9.6% |
| Total Assets | $114.07 Billion |
| Market Capitalization | $282.04 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values AstraZeneca PLC's assets at a significant premium (2.47x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: AstraZeneca PLC's assets grew by 9.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AstraZeneca PLC (1990–2025)
The table below shows the annual total assets of AstraZeneca PLC from 1990 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $114.07 Billion | +9.65% |
| 2024-12-31 | $104.03 Billion | +2.88% |
| 2023-12-31 | $101.12 Billion | +4.80% |
| 2022-12-31 | $96.48 Billion | -8.43% |
| 2021-12-31 | $105.36 Billion | +57.90% |
| 2020-12-31 | $66.73 Billion | +8.72% |
| 2019-12-31 | $61.38 Billion | +1.20% |
| 2018-12-31 | $60.65 Billion | -4.27% |
| 2017-12-31 | $63.35 Billion | +1.32% |
| 2016-12-31 | $62.53 Billion | +4.00% |
| 2015-12-31 | $60.12 Billion | +2.61% |
| 2014-12-31 | $58.59 Billion | +4.82% |
| 2013-12-31 | $55.90 Billion | +4.42% |
| 2012-12-31 | $53.53 Billion | +1.33% |
| 2011-12-31 | $52.83 Billion | -5.87% |
| 2010-12-31 | $56.13 Billion | +2.20% |
| 2009-12-31 | $54.92 Billion | +16.98% |
| 2008-12-31 | $46.95 Billion | -2.10% |
| 2007-12-31 | $47.96 Billion | +60.22% |
| 2006-12-31 | $29.93 Billion | +20.50% |
| 2005-12-31 | $24.84 Billion | -3.17% |
| 2004-12-31 | $25.65 Billion | +8.82% |
| 2003-12-31 | $23.57 Billion | +9.26% |
| 2002-12-31 | $21.58 Billion | -18.41% |
| 2001-12-31 | $26.45 Billion | +43.36% |
| 2000-12-31 | $18.45 Billion | -6.87% |
| 1999-12-31 | $19.81 Billion | +120.56% |
| 1998-12-31 | $8.98 Billion | +8.43% |
| 1997-12-31 | $8.28 Billion | -3.28% |
| 1996-12-31 | $8.56 Billion | +8.80% |
| 1995-12-31 | $7.87 Billion | +7.54% |
| 1994-12-31 | $7.32 Billion | -1.43% |
| 1993-12-31 | $7.42 Billion | +19.97% |
| 1992-12-31 | $6.19 Billion | -2.73% |
| 1991-12-31 | $6.36 Billion | +4.27% |
| 1990-12-31 | $6.10 Billion | -- |
About AstraZeneca PLC
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splend… Read more